Research Articles | Aplastic Anemia & MDS International Foundation Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Detectable mutations precede late myeloid neoplasia in aplastic anemia Feb 2021 Haematologica aplastic anemia
Luspatercept in the treatment of lower-risk myelodysplastic syndromes Jan 2021 Future Oncology (London, England) myelodysplastic syndromes (MDS)
Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options Jan 2021 Cancer Management and Research myelodysplastic syndromes (MDS)
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Jan 2021 Leukemia myelodysplastic syndromes (MDS)
Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria Jan 2021 Leukemia paroxysmal nocturnal hemoglobinuria (PNH)
How I Treat Paroxysmal nocturnal hemoglobinuria Jan 2021 Blood paroxysmal nocturnal hemoglobinuria (PNH)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes Jan 2021 Journal of clinical oncology: official journal of the American Society Clinical Oncology myelodysplastic syndromes (MDS)
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes Jan 2021 American Journal of Hematology myelodysplastic syndromes (MDS)
Treatment options for lower-risk myelodysplastic syndromes. Where are we now? Jan 2021 Therapeutic Advances in Hematology myelodysplastic syndromes (MDS)
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" Jan 2021 American Journal of Hematology myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)
Share with addtoany.com.